Full-Life Technologies Reports Positive First-in-Human Imaging Data for c-MET-Targeting Theranostic Ligand

LONDON, Oct. 19, 2026 /CourierPR/ -- Full-Life Technologies, a privately held, fully integrated, clinical-stage global radiopharmaceutical company, has announced first-in-human imaging data for its c-MET-targeting theranostic ligand, FL-261, at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM), which is being held from October 17 to 21, 2026, in Vienna, Austria.

The data, presented in a Top Rated Oral Presentation (OP-442) under the Clinical Oncology Track - Lung (Session 1006), demonstrated high lesion contrast and no tracer-related serious adverse events in 10 patients with non-small cell lung cancer (NSCLC). The first-in-human imaging data for [111In]In-FL-261 showed robust tumor uptake that increased with c-MET expression, highlighting the potential of FL-261 for diagnosing and treating patients with c-MET-expressing NSCLC.

The company has received global regulatory clearances, including from the U.S. Food and Drug Administration (FDA), Australia, and China, to advance [225Ac]Ac-FL-261 into Phase 1 clinical trials. The Phase 1 SumMET trial (NCT07873450) is set to proceed at sites in these countries for patients with non-squamous NSCLC that expresses c-MET.

The Top Rated Oral Presentation reports results from a prospective clinical trial of [111In]In-FL-261 in 10 patients with histologically confirmed NSCLC, designed to evaluate safety, biodistribution, and diagnostic performance. Patients underwent SPECT/CT imaging 4, 24, and 72 hours after injection, and had a baseline [18F]FDG PET/CT for comparison. Key findings include:

- Tumor SUVmax at 4, 24, and 72 hours was 13.8, 25.7, and 43.2 for a patient with a high c-MET immunohistochemistry (IHC) score, and 12.7, 22.9, and 20.7 for a patient with a moderate IHC score. - The ratio of tumor SUVmax versus kidney and bone marrow SUVmean was in the range of 2.8-20.3 and 17.4-72.4, respectively, for these two patients at all acquired time points. - Across six patients with available c-MET IHC scores, [111In]In-FL-261 uptake in the lesions showed a positive trend with c-MET expression (Spearman rho 0.82, P = 0.034), whereas [18F]FDG uptake did not (rho -0.13, P = 0.80). - The normal organ biodistribution was generally low and all with rapid washout. The organs with the highest uptake were the liver, spleen, and kidneys. - [111In]In-FL-261 was well tolerated in all patients, with no tracer-related serious adverse events.

In addition to the clinical imaging data, Full-Life is also presenting preclinical data (E-Poster #0035) that describe the discovery and preclinical characterization of FL-261. [111In]In-FL-261 showed potent, c-MET-specific binding and rapid internalization in c-MET-overexpressing cells and in tumor-bearing mice. Tumor uptake exceeded that of normal organs and was nearly completely blocked by unlabeled FL-261. [225Ac]Ac-FL-261 produced marked tumor regression in xenograft models with varying levels of c-MET expression, including a model derived from a patient previously treated with a c-MET-targeted antibody-drug conjugate, with no notable changes in body weight.

The SumMET Phase 1 trial, which is currently being prepared for launch, aims to evaluate the safety and efficacy of [225Ac]Ac-FL-261 in patients with non-squamous NSCLC that expresses c-MET. The trial is expected to provide valuable insights into the potential of this targeted radioconjugate for the diagnosis and treatment of c-MET-positive cancers.